ICD-10

ICD-10 code C13.1

You are here: Home > ICD-10-CM > C00-D49 > C00-C96 > C00-C75 > C00-C14 > C13

- ICD-10-CM
TABULAR LIST of DISEASES and INJURIES
- C00-D49
Neoplasms
- C00-C96
Malignant neoplasms
- C00-C75
Malignant neoplasms, stated or presumed to be primary (of specified sites), and certain specified histologies, except neuroendocrine, and of lymphoid, hematopoietic and related tissue
- C00-C14
Malignant neoplasms of lip, oral cavity and pharynx
- C13
Malignant neoplasm of hypopharynx

C13.1

Malignant neoplasm of aryepiglottic fold, hypopharyngeal aspect

ICD-10 code C13.1 for Malignant neoplasm of aryepiglottic fold, hypopharyngeal aspect

Malignant neoplasm of aryepiglottic fold, marginal zone
Malignant neoplasm of aryepiglottic fold NOS
Malignant neoplasm of interarytenoid fold, marginal zone
Malignant neoplasm of interarytenoid fold NOS
Excludes2: malignant neoplasm of aryepiglottic fold or interarytenoid fold, laryngeal aspect (C32.1)
ICD-10
ATC
ICD-10 International Statistical Classification of Diseases and Related Health Problems 10th Revision
ICD-10

ICD-10 is the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD), a medical classification list by the World Health Organization (WHO).

It contains codes for diseases, signs and symptoms, abnormal findings, complaints, social circumstances, and external causes of injury or diseases.

ATC

The Anatomical Therapeutic Chemical (ATC) Classification System is used for the classification of active ingredients of drugs according to the organ or system on which they act and their therapeutic, pharmacological and chemical properties.

It is controlled by the World Health Organization Collaborating Centre for Drug Statistics Methodology (WHOCC).

DDD

The defined daily dose (DDD) is a statistical measure of drug consumption, defined by the World Health Organization (WHO).

It is used to standardize the comparison of drug usage between different drugs or between different health care environments.

Home Contact Us